Circulating levels of endothelial progenitor cells are associated with better cognitive function in older adults with glucagon-like peptide 1 receptor agonist-treated type 2 diabetes

Miriam Longo, Irene Di Meo, Paola Caruso, Maria Francesca Muscio, Lorenzo Scappaticcio, Antonietta Maio, Maria Ida Maiorino, Giuseppe Bellastella, Giuseppe Signoriello, Filip K Knop, Maria Rosaria Rizzo, Katherine Esposito

Abstract

AIMS: To evaluate cognitive function in subjects with type 2 diabetes (T2D) treated with glucagon-like peptide 1 receptor agonist (GLP-1RA) plus metformin or metformin alone and its association with endothelial progenitor cells (EPCs).

METHODS: Adults with T2D treated with GLP-1RA plus metformin (GLP-1RA + MET) or MET alone for at least 12 months were included. Montreal Cognitive Assessment test (MoCA), Mini-Mental State Examination (MMSE), Mini Nutritional Assessment (MNA) and disability tests were administered. Circulating levels of seven EPCs phenotypes were measured by flow cytometry.

RESULTS: A total of 154 elderly patients were included, of whom 78 in GLP-1RA + MET group and 76 in MET group. The GLP-1RA + MET group showed better cognitive function as indicated by a significant higher MoCA and MMSE scores, and higher levels of CD34+ CD133+, CD133+ KDR+, and CD34+ CD133+ KDR+ as compared with MET group. The number of CD34+ CD133+ KDR+ cells was an independent predictor of higher MoCA, MMSE and MNA scores.

CONCLUSIONS: People with T2D on GLP-1RA + MET treatment had better cognitive function and higher circulating levels of EPCs as compared with those on MET alone warranting further studies to understand the interrelationship between EPCs, GLP-RA treatment and cognitive health.

OriginalsprogEngelsk
Artikelnummer110688
TidsskriftDiabetes Research and Clinical Practice
Vol/bind200
Sider (fra-til)110688
ISSN0168-8227
DOI
StatusUdgivet - jun. 2023

Fingeraftryk

Dyk ned i forskningsemnerne om 'Circulating levels of endothelial progenitor cells are associated with better cognitive function in older adults with glucagon-like peptide 1 receptor agonist-treated type 2 diabetes'. Sammen danner de et unikt fingeraftryk.

Citationsformater